Pemphigoid, Bullous
7
1
1
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
28.6%
2 terminated out of 7 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
Cytokines in Blister Fluids of Bullous Pemphigoid (BP)
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)